Physician profile
Darlene Mcnulty
NPI 1235215211
$4,757.05
in general payments reported to CMS, 2019-2025
26 companies · $656 in 2025
The $656 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $300 · 2021: $1,009 · 2022: $1,253 · 2023: $364 · 2024: $201 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.51 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.23 | 2021-2025 | |
| Lundbeck LLC | $457.99 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $451.28 | 2021-2025 | Qelbree |
| Neos Therapeutics, LP | $383.24 | 2019-2023 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $371.33 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $305.29 | 2022-2025 | Caplyta |
| Allergan, INC. | $256.42 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $239.54 | 2019-2022 | |
| Corium, LLC | $213.51 | 2022-2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $211.07 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $172.34 | 2019-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $159.92 | 2019-2022 | |
| Axsome Therapeutics, INC. | $154.79 | 2022-2025 | Auvelity |
| Tris Pharma INC | $147.52 | 2022-2024 | Dyanavel Xr |
| Almatica Pharma LLC | $119.69 | 2025 | Loreev Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $89.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $75.46 | 2022 | |
| Shire North American Group INC | $64.05 | 2019 | |
| Ironshore Pharmaceuticals INC. | $57.37 | 2019-2022 | |
| Orexo US, INC. | $45.50 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.74 | 2019 | |
| Eisai INC. | $23.63 | 2022 | |
| Aytu Biopharma, INC. | $23.40 | 2022 | |
| Alkermes, INC. | $20.96 | 2019 | |
| Adlon Therapeutics L.P. | $16.32 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darlene Mcnulty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.